仿制药-话题@MedSci

#仿制药#

261篇内容 | 5543人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1261394, encodeId=bec712613941b, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=美国拒绝罗氏Rituxan和Herceptin生物仿制药的申请, objectType=article, longId=134432, objectId=34851344321d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34851344321d, replyNumber=0, likeNumber=82, createdTime=2018-04-08, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34851344321d, moduleTitle=美国拒绝罗氏Rituxan和Herceptin生物仿制药的申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34851344321d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261393, encodeId=8bca1261393e9, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=从制药大国迈向制药强国——国家卫生健康委员会有关负责人解读仿制药管理新政四大看点, objectType=article, longId=134330, objectId=fc2c134330af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc2c134330af, replyNumber=0, likeNumber=77, createdTime=2018-04-06, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc2c134330af, moduleTitle=从制药大国迈向制药强国——国家卫生健康委员会有关负责人解读仿制药管理新政四大看点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc2c134330af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261392, encodeId=ac501261392c8, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=国家卫生健康委员会有关负责人解读仿制药管理新政四大看点, objectType=article, longId=134279, objectId=8eef1342e971, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8eef1342e971, replyNumber=0, likeNumber=61, createdTime=2018-04-06, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8eef1342e971, moduleTitle=国家卫生健康委员会有关负责人解读仿制药管理新政四大看点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8eef1342e971)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261391, encodeId=348512613916e, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=国办印发《关于改革完善仿制药供应保障及使用政策的意见》, objectType=article, longId=134218, objectId=a8a113421870, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8a113421870, replyNumber=0, likeNumber=68, createdTime=2018-04-05, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8a113421870, moduleTitle=国办印发《关于改革完善仿制药供应保障及使用政策的意见》, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8a113421870)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261390, encodeId=712c1261390b5, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=抗癌药关税有望降低：仿制药企或受冲击，创新药企空间更大, objectType=article, longId=133050, objectId=c4fe1330503e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4fe1330503e, replyNumber=0, likeNumber=56, createdTime=2018-03-23, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4fe1330503e, moduleTitle=抗癌药关税有望降低：仿制药企或受冲击，创新药企空间更大, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4fe1330503e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261389, encodeId=090a12613892c, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=一致性评价后仿制药该降价？, objectType=article, longId=131650, objectId=c4df131650af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4df131650af, replyNumber=0, likeNumber=62, createdTime=2018-03-08, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4df131650af, moduleTitle=一致性评价后仿制药该降价？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4df131650af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261388, encodeId=516e12613883c, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=创纪录！一年批准1027个仿制药, objectType=article, longId=129911, objectId=4221129911e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4221129911e9, replyNumber=0, likeNumber=74, createdTime=2018-02-15, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4221129911e9, moduleTitle=创纪录！一年批准1027个仿制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4221129911e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261387, encodeId=97d6126138ede, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=第12批仿制药参比制剂目录发布, objectType=article, longId=129737, objectId=aae4129e37f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aae4129e37f7, replyNumber=0, likeNumber=69, createdTime=2018-02-14, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aae4129e37f7, moduleTitle=第12批仿制药参比制剂目录发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aae4129e37f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261386, encodeId=274a1261386b7, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=美国并非仿制药掘金天堂有的人只是到FDA考个“证”, objectType=article, longId=129067, objectId=480912906ecf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=480912906ecf, replyNumber=0, likeNumber=61, createdTime=2018-02-08, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=480912906ecf, moduleTitle=美国并非仿制药掘金天堂有的人只是到FDA考个“证”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=480912906ecf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261385, encodeId=e85a1261385c9, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=JCO：“价廉”是否“物美”—— 曲妥珠单抗（赫赛汀）vs. 生物仿制药, objectType=article, longId=128870, objectId=4e4b1288e05f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e4b1288e05f, replyNumber=0, likeNumber=55, createdTime=2018-02-06, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e4b1288e05f, moduleTitle=JCO：“价廉”是否“物美”—— 曲妥珠单抗（赫赛汀）vs. 生物仿制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e4b1288e05f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261384, encodeId=11e51261384c3, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=中央深改组发令：改革完善仿制药供应保障及使用政策, objectType=article, longId=127678, objectId=609412e678dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=609412e678dd, replyNumber=0, likeNumber=56, createdTime=2018-01-27, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=609412e678dd, moduleTitle=中央深改组发令：改革完善仿制药供应保障及使用政策, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=609412e678dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261383, encodeId=ea38126138398, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=**层定调仿制药，彻底影响4500家药企！, objectType=article, longId=127676, objectId=f4c912e676bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4c912e676bf, replyNumber=0, likeNumber=83, createdTime=2018-01-27, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4c912e676bf, moduleTitle=**层定调仿制药，彻底影响4500家药企！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4c912e676bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261382, encodeId=68a6126138202, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=Mylan在英国推出了Copaxone仿制药, objectType=article, longId=127644, objectId=636f12e6448c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=636f12e6448c, replyNumber=0, likeNumber=43, createdTime=2018-01-26, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=636f12e6448c, moduleTitle=Mylan在英国推出了Copaxone仿制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=636f12e6448c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261381, encodeId=1f74126138155, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=中央全面深改组会议：改革完善仿制药供应保障政策, objectType=article, longId=127501, objectId=9be212e50144, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9be212e50144, replyNumber=0, likeNumber=53, createdTime=2018-01-25, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9be212e50144, moduleTitle=中央全面深改组会议：改革完善仿制药供应保障政策, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9be212e50144)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261380, encodeId=6c5612613806b, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=Avastin生物仿制药获得欧盟批准, objectType=article, longId=127348, objectId=5d1c12e348d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d1c12e348d0, replyNumber=0, likeNumber=61, createdTime=2018-01-24, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d1c12e348d0, moduleTitle=Avastin生物仿制药获得欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d1c12e348d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261379, encodeId=e93a12613e9bc, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=Sandoz和Biocon联合开发“多种”生物仿制药。, objectType=article, longId=127042, objectId=7ad712e0420d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ad712e0420d, replyNumber=0, likeNumber=68, createdTime=2018-01-21, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ad712e0420d, moduleTitle=Sandoz和Biocon联合开发“多种”生物仿制药。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ad712e0420d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261378, encodeId=7d2812613e8aa, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=医保压力向外转移，中医药、品牌仿制药将成为资本宠儿, objectType=article, longId=126545, objectId=d07812654542, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d07812654542, replyNumber=0, likeNumber=72, createdTime=2018-01-17, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d07812654542, moduleTitle=医保压力向外转移，中医药、品牌仿制药将成为资本宠儿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d07812654542)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261377, encodeId=d8ee12613e799, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=仿制药药效将比肩原研药药费有望下降, objectType=article, longId=126029, objectId=0f0f126029fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f0f126029fc, replyNumber=0, likeNumber=93, createdTime=2018-01-11, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f0f126029fc, moduleTitle=仿制药药效将比肩原研药药费有望下降, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f0f126029fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261376, encodeId=ec7412613e66b, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=全面提升仿制药质量和疗效，首批17个品规通过一致性评价, objectType=article, longId=125647, objectId=193f12564e8e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=193f12564e8e, replyNumber=0, likeNumber=84, createdTime=2018-01-06, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=193f12564e8e, moduleTitle=全面提升仿制药质量和疗效，首批17个品规通过一致性评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=193f12564e8e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261375, encodeId=c4e812613e503, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=大限将至仿制药能否觅新生, objectType=article, longId=125375, objectId=10b71253e5d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=10b71253e5d4, replyNumber=0, likeNumber=62, createdTime=2018-01-05, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=10b71253e5d4, moduleTitle=大限将至仿制药能否觅新生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=10b71253e5d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

仿制药

2020-05-29

drwjr (审核中...)

前往app查看评论内容

#仿制药#

美国拒绝罗氏Rituxan和Herceptin生物仿制药的申请

2018-04-08

drwjr (审核中...)

前往app查看评论内容

#仿制药#

从制药大国迈向制药强国——国家卫生健康委员会有关负责人解读仿制药管理新政四大看点

2018-04-06

drwjr (审核中...)

前往app查看评论内容

#仿制药#

国家卫生健康委员会有关负责人解读仿制药管理新政四大看点

2018-04-06

drwjr (审核中...)

前往app查看评论内容

#仿制药#

国办印发《关于改革完善仿制药供应保障及使用政策的意见》

2018-04-05

drwjr (审核中...)

前往app查看评论内容

#仿制药#

抗癌药关税有望降低：仿制药企或受冲击，创新药企空间更大

2018-03-23

drwjr (审核中...)

前往app查看评论内容

#仿制药#

一致性评价后仿制药该降价？

2018-03-08

drwjr (审核中...)

前往app查看评论内容

#仿制药#

创纪录！一年批准1027个仿制药

2018-02-15

drwjr (审核中...)

前往app查看评论内容

#仿制药#

第12批仿制药参比制剂目录发布

2018-02-14

drwjr (审核中...)

前往app查看评论内容

#仿制药#

美国并非仿制药掘金天堂有的人只是到FDA考个“证”

2018-02-08

drwjr (审核中...)

前往app查看评论内容

#仿制药#

JCO：“价廉”是否“物美”—— 曲妥珠单抗（赫赛汀）vs. 生物仿制药

2018-02-06

drwjr (审核中...)

前往app查看评论内容

#仿制药#

中央深改组发令：改革完善仿制药供应保障及使用政策

2018-01-27

drwjr (审核中...)

前往app查看评论内容

#仿制药#

**层定调仿制药，彻底影响4500家药企！

2018-01-27

drwjr (审核中...)

前往app查看评论内容

#仿制药#

Mylan在英国推出了Copaxone仿制药

2018-01-26

drwjr (审核中...)

前往app查看评论内容

#仿制药#

中央全面深改组会议：改革完善仿制药供应保障政策

2018-01-25

drwjr (审核中...)

前往app查看评论内容

#仿制药#

Avastin生物仿制药获得欧盟批准

2018-01-24

drwjr (审核中...)

前往app查看评论内容

#仿制药#

Sandoz和Biocon联合开发“多种”生物仿制药。

2018-01-21

drwjr (审核中...)

前往app查看评论内容

#仿制药#

医保压力向外转移，中医药、品牌仿制药将成为资本宠儿

2018-01-17

drwjr (审核中...)

前往app查看评论内容

#仿制药#

仿制药药效将比肩原研药药费有望下降

2018-01-11

drwjr (审核中...)

前往app查看评论内容

#仿制药#

全面提升仿制药质量和疗效，首批17个品规通过一致性评价

2018-01-06

drwjr (审核中...)

前往app查看评论内容

#仿制药#

大限将至仿制药能否觅新生

2018-01-05

科室
- - 订阅+
  - 更多科室
工具
服务